Help us investigate immune tolerance.
What if there was a way to help your immune system become more tolerant of gluten? That’s the potential of VTP-1000, an investigational immunotherapy being studied in the AVALON celiac disease clinical trial.
What is AVALON?
AVALON is a phase 1 clinical trial that aims to assess the safety and tolerability of the investigational drug VTP-1000 in adults with celiac disease.
What is the goal of VTP-1000?
VTP-1000 is designed to prevent or reduce celiac disease symptoms caused by accidental gluten exposure. The goal of this investigational targeted immunotherapy is to train the immune system to tolerate gluten while preserving its overall protective function.
Who can participate?
You may qualify to participate if:
- You are 18–65 years old.
- You have celiac disease confirmed by biopsy within the past 10 years.
- You have been on a gluten-free diet for 12+ months.
- You live in the US.
Additional eligibility criteria apply.
Study Locations
The AVALON Study will be conducted at several locations across the US:
- Baltimore, MD
- Los Angeles, CA
- …and more locations coming soon!
Compensation
Compensation for your time and travel may be available to help make your participation as convenient as possible.
Get Involved
Start the next chapter of your celiac disease journey by participating in AVALON, which will provide new learnings that may help future celiac disease patients.
To learn more and see if you qualify, visit avalon.celiac.org.
About the Study Sponsor
Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer. Helping people living with serious diseases and their families is the guiding principle at the heart of Barinthus Bio.
Investigating Immune Tolerance in Celiac Disease: AVALON Clinical Trial